Literature DB >> 19333762

Intranasal microemulsion of sildenafil citrate: in vitro evaluation and in vivo pharmacokinetic study in rabbits.

Ahmed H Elshafeey1, Ehab R Bendas, Osama H Mohamed.   

Abstract

The purpose of the present study was to prepare intranasal delivery system of sildenafil citrate and estimate its relative bioavailability after nasal administration in rabbits to attain rapid onset of action with good efficacy at lower doses. Sildenafil citrate saturated solubility was determined in different solvents, cosolvents, and microemulsion systems. For nasal application, sildenafil citrate was formulated in two different systems: the first was a cosolvent system (S3) of benzyl alcohol/ethanol/water/Transcutol/taurodeoxy cholate/Tween 20 (0.5:16.8:47.7:15.9:1:18.1% w/w). The second was a microemulsion system (ME6) containing Oleic acid: Labrasol/Transcutol/water (8.33:33.3:16.66:41.66% w/w). The prepared systems were characterized in relation to their clarity, particle size, viscosity, pH, and nasal ciliotoxicity. In vivo pharmacokinetic performance of the selected system ME6 (with no nasal ciliotoxicity) was evaluated in a group of six rabbits in a randomized crossover study and compared to the marketed oral tablets. The targeted solubility (>20 mg/ml) of sildenafil citrate was achieved with cosolvent systems S1, S3, and S5 and with microemulsion systems ME3-ME6. The saturated solubility of sildenafil citrate in cosolvent system S3 and microemulsion system ME6 were 22.98 +/- 1.26 and 23.79 +/- 1.16 mg/ml, respectively. Microemulsion formulation ME6 showed shorter t (max) (0.75 h) and higher AUC((0-infinity)) (1,412.42 ng h/ml) compared to the oral tablets which showed t (max) equals 1.25 h and AUC((0-infinity)) of 1,251.14 ng h/ml after administration to rabbits at dose level of 5 mg/kg. The relative bioavailability was 112.89%. In conclusion, the nasal absorption of sildenafil citrate microemulsion was found to be fast, indicating the potential of nasal delivery instead of the conventional oral administration of such drug.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19333762      PMCID: PMC2690776          DOI: 10.1208/s12249-009-9213-6

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  17 in total

1.  Pharmacokinetics and pharmacodynamics of midazolam administered as a concentrated intranasal spray. A study in healthy volunteers.

Authors:  P D Knoester; D M Jonker; R T M Van Der Hoeven; T A C Vermeij; P M Edelbroek; G J Brekelmans; G J de Haan
Journal:  Br J Clin Pharmacol       Date:  2002-05       Impact factor: 4.335

2.  Effect of high-fat breakfast and moderate-fat evening meal on the pharmacokinetics of vardenafil, an oral phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction.

Authors:  Prabhu Rajagopalan; Arthur Mazzu; Chenghua Xia; Ray Dawkins; Pavur Sundaresan
Journal:  J Clin Pharmacol       Date:  2003-03       Impact factor: 3.126

3.  Reduced inter- and intraindividual variability in cyclosporine pharmacokinetics from a microemulsion formulation.

Authors:  J M Kovarik; E A Mueller; J B van Bree; W Tetzloff; K Kutz
Journal:  J Pharm Sci       Date:  1994-03       Impact factor: 3.534

Review 4.  NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence.

Authors: 
Journal:  JAMA       Date:  1993-07-07       Impact factor: 56.272

5.  Nasal absorption of propranolol in humans.

Authors:  A Hussain; T Foster; S Hirai; T Kashihara; R Batenhorst; M Jones
Journal:  J Pharm Sci       Date:  1980-10       Impact factor: 3.534

Review 6.  Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction?

Authors:  S Doggrell
Journal:  Int J Impot Res       Date:  2006-12-21       Impact factor: 2.896

7.  [Toxicity of drugs on nasal mucocilia and the method of its evaluation].

Authors:  X G Jiang; J B Cui; X L Fang; Y Wei; N Z Xi
Journal:  Yao Xue Xue Bao       Date:  1995-11

8.  Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction.

Authors:  M Boolell; M J Allen; S A Ballard; S Gepi-Attee; G J Muirhead; A M Naylor; I H Osterloh; C Gingell
Journal:  Int J Impot Res       Date:  1996-06       Impact factor: 2.896

9.  Enhanced bioavailability of metoclopramide HCl by intranasal administration of a mucoadhesive in situ gel with modulated rheological and mucociliary transport properties.

Authors:  Noha M Zaki; Gehanne A Awad; Nahed D Mortada; Seham S Abd Elhady
Journal:  Eur J Pharm Sci       Date:  2007-08-31       Impact factor: 4.384

10.  In vitro permeation studies comparing bovine nasal mucosa, porcine cornea and artificial membrane: androstenedione in microemulsions and their components.

Authors:  Telse Richter; Sigrid Keipert
Journal:  Eur J Pharm Biopharm       Date:  2004-07       Impact factor: 5.571

View more
  14 in total

1.  Development of carbamazepine transnasal microemulsion for treatment of epilepsy.

Authors:  Sheetal Porecha Acharya; K Pundarikakshudu; Ashish Panchal; Anita Lalwani
Journal:  Drug Deliv Transl Res       Date:  2013-06       Impact factor: 4.617

2.  Self-nanoemulsifying formulation for oral delivery of sildenafil: effect on physicochemical attributes and in vivo pharmacokinetics.

Authors:  Sanyog Jain; Narinder Kumar; Reena Sharma; Rohan Ghadi; Tushar Date; Nallamothu Bhargavi; Dasharath Chaudhari; Sameer S Katiyar
Journal:  Drug Deliv Transl Res       Date:  2022-10-12       Impact factor: 5.671

3.  Comparative pharmacokinetic studies of borneol in mouse plasma and brain by different administrations.

Authors:  Jing-yi Zhao; Yang Lu; Shou-ying Du; Xiao Song; Jie Bai; Yue Wang
Journal:  J Zhejiang Univ Sci B       Date:  2012-12       Impact factor: 3.066

4.  A nanohybrid system for taste masking of sildenafil.

Authors:  Ji-Hee Lee; Goeun Choi; Yeon-Ji Oh; Je Won Park; Young Bin Choy; Mung Chul Park; Yeo Joon Yoon; Hwa Jeong Lee; Hee Chul Chang; Jin-Ho Choy
Journal:  Int J Nanomedicine       Date:  2012-03-26

5.  Improvement of fluvastatin bioavailability by loading on nanostructured lipid carriers.

Authors:  Abdel-Rahim M El-Helw; Usama A Fahmy
Journal:  Int J Nanomedicine       Date:  2015-09-16

6.  Solid lipid nanoparticles loaded with iron to overcome barriers for treatment of iron deficiency anemia.

Authors:  Khaled Mohamed Hosny; Zainy Mohammed Banjar; Amani H Hariri; Ali Habiballah Hassan
Journal:  Drug Des Devel Ther       Date:  2015-01-08       Impact factor: 4.162

7.  Optimized nano-transfersomal films for enhanced sildenafil citrate transdermal delivery: ex vivo and in vivo evaluation.

Authors:  Shaimaa M Badr-Eldin; Osamaa Aa Ahmed
Journal:  Drug Des Devel Ther       Date:  2016-04-05       Impact factor: 4.162

8.  Miconazole-loaded solid lipid nanoparticles: formulation and evaluation of a novel formula with high bioavailability and antifungal activity.

Authors:  Bader Mubarak Aljaeid; Khaled Mohamed Hosny
Journal:  Int J Nanomedicine       Date:  2016-01-25

9.  Preclinical Study of Ibuprofen Loaded Transnasal Mucoadhesive Microemulsion for Neuroprotective Effect in MPTP Mice Model.

Authors:  Surjyanarayan Mandal; Snigdha Das Mandal; Krishna Chuttani; Krutika K Sawant; Bharat Bhushan Subudhi
Journal:  Iran J Pharm Res       Date:  2018       Impact factor: 1.696

10.  Optimization of carvedilol solid lipid nanoparticles: An approach to control the release and enhance the oral bioavailability on rabbits.

Authors:  Khalid Mohamed El-Say; Khaled Mohamed Hosny
Journal:  PLoS One       Date:  2018-08-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.